Drug
Ly3537982
Ly3537982: highest development phase Phase 1/2, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY3537982 NCT04956640 | Phase 1/2 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow Ly3537982 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.